A randomized, double-blind, placebo-controlled, multicenter phase II study to compare the efficacy and safety of sorafenib added to standard treatment with topotecan to standard treatment alone in patients with platinum-resistant recurrent ovarian cancer (TRIAS): Results of a NOGGO-AGO intergroup pilot-study.
K. El Khalfaoui
No relevant relationships to disclose
S. Mahner
No relevant relationships to disclose
R. Richter
No relevant relationships to disclose
F. Hilpert
No relevant relationships to disclose
R. Lorenz
No relevant relationships to disclose
P. Harter
No relevant relationships to disclose
P. Klare
No relevant relationships to disclose
U. A. G. Wagner
No relevant relationships to disclose
R. Chekerov
No relevant relationships to disclose
J. Sehouli
No relevant relationships to disclose